Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACSTNASDAQ:AEZSNYSE:NBYNASDAQ:RGC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACSTAcasti Pharma$3.11$3.22$1.98▼$3.60$29.23M1.5222,722 shs12,261 shsAEZSAeterna Zentaris$3.41-0.6%$3.50$3.96▼$12.00$6.11M1.557,305 shs2,601 shsNBYNovaBay Pharmaceuticals$0.63+0.6%$0.59$0.36▼$2.45$3.66M0.43122,618 shs8,792 shsRGCRegencell Bioscience$22.99+121.9%$0.00$0.08▼$83.60$5.12B2.291.56 million shs18.80 million shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACSTAcasti Pharma0.00%0.00%0.00%-7.72%+7.24%AEZSAeterna Zentaris-0.58%+1.79%-6.58%+25.60%-22.68%NBYNovaBay Pharmaceuticals+0.62%+4.83%+12.89%+21.71%-71.01%RGCRegencell Bioscience+121.91%+13.87%+2,298,999,900.00%+2,298,999,900.00%+2,298,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACSTAcasti PharmaN/AN/AN/AN/AN/AN/AN/AN/AAEZSAeterna ZentarisN/AN/AN/AN/AN/AN/AN/AN/ANBYNovaBay Pharmaceuticals2.0632 of 5 stars3.50.00.00.00.01.71.3RGCRegencell Bioscience0.3953 of 5 stars0.03.00.00.02.80.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACSTAcasti Pharma 3.00Buy$10.00221.54% UpsideAEZSAeterna Zentaris 0.00N/AN/AN/ANBYNovaBay Pharmaceuticals 3.00Buy$0.8535.14% UpsideRGCRegencell Bioscience 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACSTAcasti PharmaN/AN/AN/AN/A$6.57 per shareN/AAEZSAeterna Zentaris$2.37M2.58N/AN/A$14.99 per share0.23NBYNovaBay Pharmaceuticals$9.78M0.37N/AN/A$4.25 per share0.15RGCRegencell BioscienceN/AN/AN/AN/A$0.02 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACSTAcasti Pharma-$12.85M-$1.44N/AN/AN/AN/A-13.61%-11.56%N/AAEZSAeterna Zentaris-$16.55M-$14.86N/A∞N/A-760.32%-83.45%-45.76%8/11/2025 (Estimated)NBYNovaBay Pharmaceuticals-$9.64M-$53.72N/AN/AN/A-102.72%-7,293.78%-158.41%N/ARGCRegencell Bioscience-$4.30MN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACSTAcasti PharmaN/AN/AN/AN/AN/AAEZSAeterna ZentarisN/AN/AN/AN/AN/ANBYNovaBay PharmaceuticalsN/AN/AN/AN/AN/ARGCRegencell BioscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACSTAcasti PharmaN/A7.867.86AEZSAeterna ZentarisN/A5.945.93NBYNovaBay PharmaceuticalsN/A1.150.91RGCRegencell BioscienceN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACSTAcasti Pharma6.08%AEZSAeterna Zentaris0.73%NBYNovaBay Pharmaceuticals23.25%RGCRegencell Bioscience0.13%Insider OwnershipCompanyInsider OwnershipACSTAcasti Pharma13.51%AEZSAeterna Zentaris0.10%NBYNovaBay Pharmaceuticals0.10%RGCRegencell Bioscience2.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACSTAcasti Pharma329.40 million8.77 millionNot OptionableAEZSAeterna Zentaris201.79 million1.79 millionNo DataNBYNovaBay Pharmaceuticals305.82 million4.88 millionNot OptionableRGCRegencell Bioscience10494.49 million484.60 millionN/ANBY, RGC, AEZS, and ACST HeadlinesRecent News About These CompaniesRGC - Regencell Bioscience Holdings Ltd Financials | MorningstarJuly 3 at 9:39 PM | morningstar.comMRegencell stock rally returns as company blames short selling for volatilityJuly 3 at 4:34 PM | msn.comChinese Stocks To Add to Your Watchlist - July 3rdJuly 3 at 1:46 PM | marketbeat.comRegencell Bioscience Appoints New Independent Director Amid Board ChangesJune 30, 2025 | tipranks.comRegencell Bioscience Reports Improved Financial Results for First Half of 2025June 30, 2025 | tipranks.comMystery $42 billion Chinese medical fortune collapses in daysJune 27, 2025 | msn.comRegencell's 82,000% Surge: The $33 Billion Stock Rally That Nobody Can ExplainJune 27, 2025 | finance.yahoo.comRegencell Bioscience Holdings Limited (RGC) - Yahoo FinanceJune 26, 2025 | finance.yahoo.comRGC - Regencell Bioscience Holdings Ltd Price vs Fair Value | MorningstarJune 26, 2025 | morningstar.comMRegencell Bioscience (NASDAQ:RGC) Trading Down 3.5% - Here's WhyJune 26, 2025 | marketbeat.comRegencell Bioscience Holdings Ltd (RGC)June 22, 2025 | investing.comRegencell Bioscience Holdings (NasdaqCM:RGC) Announces 38:1 Stock Split Effective June 2025June 20, 2025 | finance.yahoo.comThe company recently effected a 38-for-1 forward stock splitJune 20, 2025 | msn.comWhy This Chinese Herbal Medicine Stock Backed by BlackRock and Morgan Stanley Gained 50,000% in 6 Months Despite Posting LossesJune 20, 2025 | msn.comA Chinese herbal-medicine stock with no revenue has surged 60,000% this year. 5 things to know about the company's mysterious spike.June 20, 2025 | msn.comPrediction: Wall Street's Latest Stock-Split Stock -- Up 60,120% Year-to-Date -- Is Going to ImplodeJune 20, 2025 | fool.comRegencell Bioscience: Fundamentals And Meme Stock Potential Are Both LackingJune 18, 2025 | seekingalpha.comRegencell Bioscience: The Most Overvalued Stock In BiotechJune 3, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNBY, RGC, AEZS, and ACST Company DescriptionsAcasti Pharma NASDAQ:ACSTAcasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.Aeterna Zentaris NASDAQ:AEZS$3.41 -0.02 (-0.58%) As of 07/2/2025Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.NovaBay Pharmaceuticals NYSE:NBY$0.63 +0.00 (+0.62%) As of 07/3/2025 03:30 PM EasternNovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.Regencell Bioscience NASDAQ:RGC$22.99 +12.63 (+121.91%) As of 07/3/2025 01:00 PM EasternRegencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
